Drug Profile
ACT 451840
Alternative Names: ACT-451840; Malaria therapy - ActelionLatest Information Update: 27 Jun 2017
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals; Swiss Tropical and Public Health Institute
- Developer Actelion Pharmaceuticals
- Class Antimalarials; Piperazines; Small molecules
- Mechanism of Action Aspartic endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Malaria
Most Recent Events
- 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
- 02 May 2016 No development reported - Phase-I for Malaria (In volunteers) in Australia (PO)
- 02 May 2016 No development reported - Phase-I for Malaria (In volunteers) in France (PO)